Evotec and Bristol Myers Squibb have announced progress in their strategic protein degradation partnership.
Predictive Oncology and Cancer Research Horizons have partnered to pursue development of cancer drugs utilizing the PEDAL platform.
FDA is seeking $7.2 billion to enhance food safety and advance medical product availability.
Sumitovant Bipharma has completed its acquisition of Myovant Sciences for approximately $1.7 billion.
Silicon Valley Bank has collapsed, leaving many biotechnology companies unsure of the future.
Catalent is expanding its UpTempo AAV platform to accelerate the development of gene therapies.
Vetter has become a participant of the UN Global Compact Network.
Janssen has received a positive opinion from EMA for AKEEGA plus prednisone or prednisolone for the treatment of BRCA1/2 gene-mutated metastatic castration resistant prostate cancer.
BFS technology can help maintain sterility during the biologics manufacturing process.